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Background. Functional remediation is a novel intervention with demonstrated efficacy at improving functional out-
come in euthymic bipolar patients. However, in a previous trial no significant changes in neurocognitive measures
were detected. The objective of the present analysis was to test the efficacy of this therapy in the enhancement of neuro-
psychological functions in a subgroup of neurocognitively impaired bipolar patients.
Method. A total of 188 out of 239 DSM-IV euthymic bipolar patients performing below two standard deviations from
the mean of normative data in any neurocognitive test were included in this subanalysis. Repeated-measures analyses of
variance were conducted to assess the impact of the treatment arms [functional remediation, psychoeducation, or treat-
ment as usual (TAU)] on participants’ neurocognitive and functional outcomes in the subgroup of neurocognitively
impaired patients.
Results. Patients receiving functional remediation (n = 56) showed an improvement on delayed free recall when
compared with the TAU (n = 63) and psychoeducation (n = 69) groups as shown by the group × time interaction at
6-month follow-up [F2,158 = 3.37, degrees of freedom (df) = 2, p = 0.037]. However, Tukey post-hoc analyses revealed
that functional remediation was only superior when compared with TAU (p = 0.04), but not with psychoeducation
(p = 0.10). Finally, the patients in the functional remediation group also benefited from the treatment in terms of func-
tional outcome (F2,158 = 4.26, df = 2, p = 0.016).
Conclusions. Functional remediation is effective at improving verbal memory and psychosocial functioning in a sample
of neurocognitively impaired bipolar patients at 6-month follow-up. Neurocognitive enhancement may be one of the
active ingredients of this novel intervention, and, specifically, verbal memory appears to be the most sensitive function
that improves with functional remediation.
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Introduction
The relationship between poorer course of bipolar
disorder and greater neurocognitive impairment has
been previously reported (Martinez-Aran et al. 2007;
Lopez-Jaramillo et al. 2010), as well as the impact of
neurocognitive deficits on psychosocial functioning
(Tabares-Seisdedos et al. 2008; Bonnin et al. 2010;
Depp et al. 2012; Torrent et al. 2012). As a consequence
of these findings, the interest in the development of
therapeutic strategies that contribute to restoring or
mitigating the impact of sustained neurocognitive and
functional impairment has grown in the last few years
(Fuentes-Dura et al. 2012; Vieta, 2014). However, only
twopublications have addressed this issue so far inwell-
defined samples of bipolar patients. An open study,
using a programme called Cognitive Rehabilitation
(Deckersbach et al. 2010) and a randomized controlled
trial, implementing a programme named Functional
Remediation (Torrent et al. 2013). Both studies reported
the positive impact of the interventions on functional
outcomes but the improvement of neurocognition was
mild (Deckersbach et al. 2010) or non-significant at
6-month follow-up (Torrent et al. 2013). Specifically,
Deckersbach et al. (2010) reported an improvement in re-
sidual depressive symptoms, occupational and psycho-
social functioning. Moreover, changes in executive
functioning accounted, in part, for the improvements
in occupational functioning. In a multicentre trial car-
ried out by Torrent et al. (2013) no significant effect of
treatment group was found on neurocognitive vari-
ables, despite significant improvements in psychosocial
functioning. The authors hypothesized that this result
was most likely due to the study design which did not
require a defined cognitive impairment but functional
impairment at study entry. Hence, a number of patients
showing functional but not cognitive impairment at en-
rolment may have caused ceiling effects on cognitive
measures. Due to an important heterogeneity in the se-
verity of neurocognitive impairment in bipolar disorder
(Altshuler et al. 2004; Martino et al. 2008, 2014), we
decided to conduct a subanalysis of the original multi-
centre randomized controlled trial by Torrent et al.
(2013), to analyse the response to functional remediation
in terms of neurocognitive performance. This sub-
sample consisted of patients who performed below 2
standard deviations from the mean of normative data
in any neurocognitive test. The main objective was to
ascertain whether neurocognitive enhancement was a
potential ingredient of functional remediation, given
the high density of neurocognitive tasks involved in
the therapy. We hypothesized that the group of neuro-
cognitively impaired patients receiving functional re-
mediation would improve not only their functional
outcome but also their neurocognitive functioning, as
compared with patients who were randomized to psy-
choeducation or treatment as usual (TAU).
Method
Participants
Participants in the original trial fulfilled the following
inclusion criteria (Torrent et al. 2013): (1) diagnosed
with bipolar I or II disorder (BD-I or BD-II) according
to the Diagnostic and Statistical Manual of Mental
Disorders (fourth edition, text revision; American
Psychiatric Association, 2000); (2) assessed during
euthymia defined as Young Mania Rating Scale
(YMRS) score 46 (Young et al. 1978; Colom et al.
2002), and Hamilton Depression Rating Scale-17
(HAMD) score 48 (Hamilton, 1960; Ramos-Brieva &
Cordero-Villafáfila, 1986); (3) suffering from at least a
moderate level of functional impairment measured
by means of the Functioning Assessment Short Test
(FAST) scale 5 18 (Rosa et al. 2007), including a score
of four points or more in the cognitive functioning do-
main of the FAST.
Exclusion criteria were: (1) an intelligence quotient
(IQ) < 85 or any medical condition that could affect
neuropsychological performance (such as neurological
diseases); (2) any co-morbid psychiatric condition, in-
cluding substance abuse or dependence within the
past 3 months; (3) electroconvulsive therapy within
the past year; or (4) participation in any structured psy-
chological intervention, such as psychoeducation or
cognitive remediation, within the past 2 years.
As mentioned in the original study, all patients pro-
vided written informed consent. Ethical approval for
the study was granted by the Ethics Committee at
every hospital involved in the study.
For the specific purpose of this study, we applied the
criteria of Martino et al. (2008) to assess neurocognitive
impairment in the original sample (n = 239), resulting
in 188 neurocognitively impaired patients.
Further details of this procedure are explained in the
data analysis section.
Interventions
Patients in the original trial (Torrent et al. 2013) were
assigned in a 1:1:1 ratio to receive 21weeks of functional
remediation, psychoeducation, or TAU. Randomization
was stratified by age, sex and education level.
Functional remediation
The functional remediation programme consisted of 21
weekly sessions, each lasting 90 min. This intervention
addresses neurocognitive issues such as attention,
memory and executive functions, but it focuses even
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more on enhancing functioning in daily routine. The
content of the intervention is based on ecological
tasks to be performed in two settings, in the clinic as
well as at home. Patients were trained with exercises
for memory, attention, problem solving and reasoning
and organization in order to improve their functional
outcome. Most of the techniques were based on
paper-and-pencil tasks and group activities. For
detailed information on the rationale of this interven-
tion, see Martínez-Arán et al. (2011), Bonnin et al.
(2014) and Vieta et al. (2014).
Psychoeducation
The psychoeducation also consisted of 21 weekly ses-
sions of 90 min each, aimed at preventing recurrences
of bipolar illness by improving four main issues: illness
awareness, treatment adherence, early detection of
prodromal symptoms of relapse, and lifestyle regular-
ity (Colom et al. 2003; Colom & Vieta, 2006).
TAU
In the TAU group, participants received prescribed
pharmacological treatment without any adjunctive
psychological therapy.
Clinical, neuropsychological and functional
assessment
Clinical, neurocognitive and functional variables were
collected for all patients both at baseline and at
6 months follow-up (see Torrent et al. 2013).
Clinical variables were gathered through a clinical
interview and from clinical history records. In addition
to this, the HAMD and YMRS were administered to as-
sess affective symptoms.
Neurocognitive performance was evaluated through
a comprehensive neuropsychological battery. The
same battery was administered at baseline and at
6-month follow-up. It was composed of six domains:
(1) estimated IQ, which was evaluated with the
Wechsler Adult Intelligence Scale – III (WAIS-III) vo-
cabulary subtest (Wechsler, 1997a); (2) the processing
speed index, which consists of two subtests of the
WAIS-III, the digit–symbol coding and symbol search
(Wechsler, 1997a); (3) executive function, which was
tested by set shifting, verbal fluency, planning, and re-
sponse inhibition using the Computerized Wisconsin
Card Sorting Test (Heaton, 1981), the Stroop Color–
Word Interference Test (Golden, 1978), the phonemic
(F-A-S) and categorical (animal naming) components
of the Controlled Oral Word Association Test (Benton
& Hamsher, 1976), the Trail Making Test, part B
(Reitan, 1958), and the Rey–Osterrieth Complex
Figure (Rey, 1997); (4) visual memory and verbal
learning/memory, which were assessed with the Rey–
Osterrieth Complex Figure for visual memory and
the California Verbal Learning Test (CVLT) (Delis
et al. 1987) and the Logical Memory Scale (Wechsler
Memory Scale-III; WMS-III) (Wechsler, 1997b) for
learning/memory; (5) the working memory index,
which was tested with three subtests of the WAIS-III
(Wechsler, 1997a): arithmetic, digits forward and
backward, and letter–number sequencing; and (6) at-
tention, which was tested with the Trail Making Test,
part A (Reitan, 1958), administered together with the
Continuous Performance Test-II, version 5 (Conners,
2000), to measure sustained attention.
Finally, psychosocial functioning was assessed by
means of the FAST scale (Rosa et al. 2007).
Data analysis
Datawere analysed using SPSS v.18 forWindows (USA).
First, the proportion of patients with neurocognitive im-
pairmentwas calculated following the criteria established
by Martino et al. (2008). According to their criteria, a
domain was compromised when performance in any
test of that domain was below 2 standard deviations or
more from the mean of normative data of each test.
In our sample, patients’ z scores on each measure
were calculated according to data from a healthy con-
trol group (n = 30) that was comparable in terms of age
(mean = 40.6, S.D. = 13.1, F3,262 = 0.08, p = 0.77), estimated
IQ (mean = 109.6, S.D. = 8.0, F3,261 = 2.7, p = 0.04) and
years of education (mean = 13.7, S.D. = 3.8, F3,260 = 0.51,
p = 0.47) with the remaining groups: functional
remediation (n = 77); psychoeducation (n = 82); and
TAU (n = 80). Even though significant differences
were found in the estimated IQ, when a Tukey post-hoc
test was performed, no significant differences were
found between groups. Note that these comparisons
were run with the total sample, before excluding the
patients without neurocognitive impairment.
After excluding the patients without neurocognitive
impairment, we proceeded with the second part of the
analysis. Clinical and sociodemographic variables
were analysed using one-way analysis of variance
(ANOVA) for continuous variables or the χ2 test
for categorical variables. Finally, repeated-measures
ANOVAs were conducted in order to assess the impact
of the treatment arms (functional remediation, psy-
choeducation and TAU) on participants’ scores in the
different neuropsychological variables and psycho-
social functioning at baseline and at follow-up.
Repeated-measures analysis only took into account
complete cases; hence missing cases due to being lost
to follow-up were not analysed. Raw scores were
used to compare the three groups since they did not
differ in terms of confounding variables.
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For the neuropsychological assessment, the follow-
ing neuropsychological variables were analysed in
order to cover the main cognitive domains that have
been reported to be affected in bipolar disorder (verbal
memory, attention and executive functions) (Bourne
et al. 2013) and on neurocognitive domains we work
on in the functional remediation programme: short
free recall, short cued recall, delayed free recall,
delayed cued recall, Trail Making Test part A and B,
Wisconsin Card Sorting Test perseverative errors,
Stroop interference, categorical and phonemic fluen-
cies. Between- and within-effect sizes were calculated
for each neurocognitive variable that was examined.
For psychosocial functioning, only global scores mea-
sured by means of the FAST were analysed conducting
another repeated-measure analysis.
The trial is registered under Clinicaltrials.gov iden-
tification number: NCT 01370668.
Results
Rate of neurocognitive impairment
Considering the patients who fulfilled the criteria of
Martino et al. (2008), we found that from the original
sample (n = 239) only 20% of patients (n = 51) were
free of neurocognitive impairment, that is, they did
not present any impaired cognitive domain and they
were excluded from the present study in order to
avoid ceiling effects. The remaining patients (n = 188)
presented cognitive impairment and they were
allocated to the groups as follows: 56 patients in the
functional remediation group; 69 patients in the psy-
choeducation group; and 63 patients in the TAU
group. Of note is that there is a broad range of neuro-
cognitive impairment in this sample, highlighting the
heterogeneity of neurocognitive impairment that can
be observed in bipolar disorder. As shown in Fig. 1,
rates of neurocognitive impairment were equally dis-
tributed in the three groups (χ2 = 2.45, p = 0.65).
Clinical and sociodemographic variables
As shown in Table 1, all three patient groups were
comparable in terms of sociodemographic (age, years
of education, and pre-morbid IQ estimation) and clin-
ical variables (number and type of episodes, chronicity,
age at onset, HAMD, YMRS and FAST scores).
Attrition rates
During the intervention a total of 27 patients discontin-
ued the study, distributed as follows: 14.3% (n = 8),
11.6% (n = 8) and 17.5% (n = 11) in the functional re-
mediation, psychoeducation and TAU groups, respect-
ively. These rates were not significantly different
between groups (χ2 = 0.92, p = 0.63). The main reason
for discontinuation was being lost to follow-up.
Finally, extra analyses were performed between drop-
outs and completers regarding their clinical and socio-
demographic characteristics at baseline. No differences
were found between both groups in terms of these
variables indicating that the drop-out patients were
not a source of bias for the present analyses.
Treatment effects on neurocognitive variables and
functional outcome
Compared with participants receiving TAU or psy-
choeducation, those who attended functional remedi-
ation improved in delayed free recall on the CVLT at
6-month follow- up, as shown by the significant
group x time interaction in the repeated-measures ana-
lysis (F2,158 = 3.37, p = 0.04) (see Fig. 2 and Table 2).
Tukey post-hoc analyses revealed that functional
remediation group was only superior when compared
with TAU (p = 0.04) but not to psychoeducation (p =
0.10). The between-groups effect size was small
(Cohen’s d = 0.2 and 0.3 for functional remediation v.
TAU and psychoeducation, respectively). However,
the within-group effect size, the comparison of pre-
and post-treatment, in the functional remediation
was moderate (Cohen’s d = 0.64), in psychoeducation
the within-group effect size was small (Cohen’s
d = 0.26) and in the TAU group it was small too
(Cohen’s d = 0.39).
No statistically significant differences were found
in the remaining comparisons of neurocognitive vari-
ables, although a trend was detected in the group ×
time interaction towards an improvement in favour
of the functional remediation group in verbal learning
Fig. 1. Rates of neurocognitive impairment. TAU, Treatment
as usual.
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(F2,158 = 2.8, p = 0.064) (Table 2), showing a medium
within-group effect size (Cohen’s d = 0.6). The
between-groups effect size at follow-up was small for
functional remediation when compared with both the
TAU (Cohen’s d = 0.3) and psychoeducation (Cohen’s
d = 0.4) groups.
The group receiving functional remediation also
improved significantly their functional outcome when
compared with psychoeducation and TAU as shown
by the group x time interaction (F2,158 = 4.26, p =
0.016). These results do not differ from the original
study (Torrent et al. 2013). See Fig. 3 for further details.
Changes in the FAST scale and changes in the CVLT
free delayed recall were not significantly correlated (r =
0.10, p = 0.22). However, at the end of the study there
was a significant association between higher FAST
total score and lower free delayed score in the CVLT
(r =−0.25, p = 0.002). Finally, changes in CVLT free
delayed recall did not correlate with changes in
HAMD total score (r = 0.17, p = 0.29) or with YMRS
total score (r = 0.14, p = 0.39).
Discussion
The main result of this study was that participants
selected for being neurocognitively impaired improved
after the administration of functional remediation.
Specifically, they presented better performance in
Table 1. Clinical and sociodemographic characteristics
Functional
remediation (n = 56)
Psychoeducation
(n = 69) TAU (n = 63)
Statistics
F or χ2 p
Age, years 40.7 (9.2) 39.3 (9.2) 39.9 (9.3) F2,183 = 0.36 0.70
Estimated IQ 102.8 (12.1) 101.7 (10.9) 104.8 (14.1) F2,184 = 1.06 0.35
Years of education 12.3 (4.2) 12.8 (3.5) 12.8 (3.6) F2,182 = 0.40 0.05
Age at onset, years 26.3 (8.1) 26.5 (8.9) 24.2 (7.7) F2,183 = 1.41 0.24
Number of previous hospitalizations 3.0 (3.5) 2.6 (2.5) 2.6 (2.2) F2,182 = 0.48 0.61
Number of previous manias 2.1 (4.3) 2.1 (4.0) 2.0 (3.6) F2,182 = 0.15 0.86
Number of previous depressions 4.9 (6.5) 4.3 (5.6) 5.7 (6.4) F2,182 = 0.89 0.41
Years of illness 14.3 (8.9) 12.7 (9.1) 15.7 (8.9) F2,120 = 1.80 0.16
HAMD scores 3.9 (2.6) 4.4 (2.6) 4.3 (2.5) F2,184 = 0.70 0.49
YMRS scores 1.3 (1.7) 1.7 (1.9) 1.3 (1.7) F2,184 = 1.07 0.34
FAST scores 31.5 (10.0) 31.1 (10.8) 29.5 (9.4) F2,185 = 0.63 0.53
Gender: female, n (%) 33 (58.9) 42 (60.9) 37 (58.7) χ2 = 0.07 0.96
Bipolar subtype: type I, n (%) 44 (78.6) 49 (73.1) 47 (77.0) χ2 = 0.54 0.76
Lifetime psychotic symptoms, n (%) 33 (58.9) 43 (64.2) 44 (71.0) χ2 = 1.89 0.38
Family history of affective disorders, n (%) 31 (56.4) 42 (61.8) 38 (61.3) χ2 = 0.43 0.80
Axis II co-morbidity, n (%) 2 (3.6) 4 (6.1) 2 (3.4) χ2 = 0.64 0.72
Medication, n (%)
Stabilizer + antipsychotic 15 (26.8) 18 (26.1) 23 (36.5) χ2 = 2.05 0.36
Stabilizer + antipsychotic + benzodiazepine 8 (14.3) 15 (21.7) 11 (17.5) χ2 = 1.18 0.55
Stabilizer + atypical + antidepressant 8 (14.3) 7 (10.1) 5 (7.9) χ2 = 1.28 0.52
Monotherapy: either atypical or mood stabilizer 9 (16.1) 4 (5.8) 9 (14.3) χ2 = 3.77 0.15
Combination of two stabilizers 3 (5.4) 5 (7.2) 2 (3.2) χ2 = 1.08 0.58
Stabilizer + antidepressant + benzodiazepine 7 (12.5) 8 (11.6) 6 (9.5) χ2 = 0.28 0.86
Other combinations 3 (5.4) 11 (15.9) 4 (6.3) χ2 = 5.13 0.07
Data are given as mean (standard deviation) unless otherwise indicated.
TAU, Treatment as usual; IQ, intelligence quotient; HAMD, Hamilton Depression Rating Scale; YMRS, Young Mania
Rating Scale; FAST, Functioning Assessment Short Test.
Fig. 2. Changes in delayed free recall at 6-month follow-up.
TAU, Treatment as usual; CVLT, California Verbal Learning
Test.
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verbal memory measures such as the delayed free re-
call measured by the CVLT only when compared
with TAU, with a moderate effect size (Cohen’s d =
0.6). Although not significant, a trend in improving
verbal learning was in the same direction. In addition
to this, patients in the functional remediation group
also improved their psychosocial functioning, which
was the primary outcome of the original trial.
Overall, it seems that functional remediation, when ap-
plied to neurocognitively impaired patients, enhances
not only functional outcome but also verbal memory,
and, more specifically, learning and delayed free recall.
There may be different reasons to explain why func-
tional remediation improvesverbalmemoryparticularly.
First, this intervention involves training exercises
related to memory and learning skills, such as associ-
ation, categorization and mental imagery. This module
represents almost one-third of the whole intervention
and it is the most extensive part when compared
with the remaining neurocognitive training sessions.
Furthermore, of all the neuropsychological functions
involved, verbal memory is perhaps the most sensitive
function related to the enhancement of psychosocial
functioning, especially when measured with the
CVLT, since there is an international agreement
(International Society for Bipolar Disorders-Battery for
Assessment of Neurocognition; ISBD-BANC) on this
test as the most suitable one to assess verbal learning
and memory in bipolar disorder (Yatham et al. 2010).
These results introduce a clinically relevant topic in the
field of the rehabilitation of psychiatric patients
Table 2. Neuropsychological outcomes at baseline and at 6-month follow-up















(n = 52) F p
Verbal learning
(lists 1–5)
46.8 (13.4) 54.4 (11.8) 48.8 (9.4) 49.3 (11.2) 48.4 (12.1) 50.8 (12.4) F2,158 = 2.8 0.06
Short free recall 9.9 (3.2) 11.5 (3.5) 9.9 (2.9) 11 (2.9) 10.2 (3.4) 11.6 (3.4) F2,158 = 0.28 0.75
Short cued recall 11.4 (2.8) 13.0 (2.4) 11.3 (2.3) 12.1 (2.5) 11.3 (2.9) 12.8 (3.1) F2,158 = 2.05 0.13
Delayed free
recall
10.3 (3.4) 12.4 (3.1) 10.5 (2.7) 11.6 (2.8) 10.8 (3.4) 11.7 (3.3) F2,158 = 3.37 0.04
Delayed cued
recall
11.4 (3.19) 13.1 (2.6) 11.1 (2.9) 12.3 (2.7) 11.3 (3.2) 12.6 (3.1) F2,158 = 0.51 0.59
Trail Making Test
– part A
47.9 (23.4) 43.5 (42.1) 48.7 (28.4) 43.4 (22.9) 44.2 (26.3) 41.4 (18.8) F2,156 = 0.16 0.85
Trail Making Test
– part B




22.9 (16.6) 16.3 (12.1) 23.6 (22.6) 21.3 (18.0) 24.3 (17.5) 23.5 (21.1) F2,158 = 1.05 0.33
SCWT
interference
−0.9 (69.4) 6.7 (13.0) −1.7 (8.3) 6.31 (10.7) −0.9 (8.7) 6.1 (11.4) F2,158 = 0.06 0.94
F-A-Sa 33.7 (13.5) 34.6 (14.2) 32.1 (11.1) 32.3 (10.1) 31 (12.8) 33.4 (7.0) F2,158 = 0.65 0.52
Animal naminga 18.8 (6.0) 18.6 (5.7) 17.8 (6.1) 17.7 (5.1) 18.3 (5.1) 18.6 (5.6) F2,152 = 0.17 0.83
Data are given as mean (standard deviation).
TAU, Treatment as usual; WCST, Wisconsin Card Sorting Test; SCWT, Stroop Color and Word Test.
a Phonemic (F-A-S) and categorical (animal naming) components of the Controlled Oral Word Association Test.
Fig. 3. Improvement of functional outcome. TAU,
Treatment as usual; FAST, Functioning Assessment Short
Test.
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which is whether the level of neurocognitive impair-
ment may influence the response to psychological
interventions or not. According to our results, neuro-
cognitively impaired bipolar patients not only
improved in psychosocial functioning, but also in
delayed free recall. The fact that most of these patients
were chronic with a long duration of illness and mul-
tiple episodes suggests that functional remediation
may be effective in later stages of the illness. This is
at odds with the results of Deckersbach et al. (2010),
who found that patients with neurocognitive impair-
ment benefit less from their cognitive rehabilitation.
However, patients in that trial were mildly symptom-
atic, which can influence neuropsychological and func-
tional outcome (Bonnin et al. 2012). Regarding the
present results, it is worth mentioning that the changes
in delayed free recall were not correlated with changes
in functional outcome. This was an unexpected result,
since it has been consistently found that verbal mem-
ory impairment is related to worse functional outcome
(Martínez-Arán et al. 2007; Martino et al. 2009; Bonnin
et al. 2010). Even though these are preliminary results,
we have different hypotheses that may explain this
lack of relationship between the two variables: first, it
might be attributed to the loss of statistical power
due to small sample size in the functional remediation
group. Second, these results may suggest that, at least,
in patients with neurocognitive impairment, the im-
provement of verbal memory (delayed free recall)
and the improvement of functional outcome are in-
dependent from each other; despite the neurocogni-
tive changes being subtle, patients have acquired a
broad range of strategies to cope with difficulties in
daily life. Controversially, in a recent study of func-
tional remediation, a correlation between neurocogni-
tive changes and functional outcome was found at
12-month follow-up (Bonnín et al. in press). In light
of this, it may be hypothesized that the 6-month
follow-up is not long enough to detect significant cor-
relations and that the consolidation of learned skills
requires time. It may depend mainly on training and
sustained practice of such strategies that become evi-
dent at 12-month follow-up. Finally, changes in verbal
memory were not related either to changes in mood
symptomatology, measured by means of the HAMD
and the YMRS scores changes.
The high rate of impaired bipolar patients fulfilling
criteria for neurocognitive impairment may sound
bad news for the field; however, this result is most
probably due to different artifacts of this subanalysis.
First, it may be related to the inclusion criteria in the
original study by Torrent et al. (2013), which required
a high level of functional impairment and as a conse-
quence of this, more severe patients were selected.
Second, it may also be related to the cut-off we have
used to establish neurocogntive impairment (Martino
et al. 2008). There is a great variability in the literature
using different cut-offs to establish neurocognitive im-
pairment (van der Werf-Eldering et al. 2010; Hellvin
et al. 2012; Martino et al. 2014; Volkert et al. 2015).
The application of one or other criteria will inevitably
lead not only to different results but also to different
rates of neurocognitive impairment (Altshuler et al.
2004; Reichenberg et al. 2009; Burdick et al. 2014).
One of the limitations of the criteria used for the
present study is that the criteria of Martino et al.
(2008), together with other previous studies (Hellvin
et al. 2012; Volkert et al. 2015), might be among the
less restrictive ones in the literature, especially with re-
spect to other works that evaluate neurocognitive im-
pairment in healthy controls where the occurrence of
a single impaired test score on a neuropsychological
battery is not uncommon (Binder et al. 2009; Iverson
et al. 2011). However, using the criteria of Martino
et al. (2008) in the present study ensured that the 20%
of patients excluded to perform this analysis were the
ones with the most preserved neurocognitive perform-
ance of the sample and allowed us to include all the
heterogeneity in the neurocognitive impairment that
can be observed in bipolar disorder (Martino et al.
2014). Because of this, the present results should be
interpreted with caution and they also highlight the
need to achieve a consensus about the cut-off to estab-
lish neurocognitive impairment in bipolar disorder.
Similarly, the fact that 80% of the patients from the
Torrent et al. (2013) study qualified for this subanalysis
[compared with 62% in the Martino et al. (2014) study,
using the same criteria] may be attributable to different
reasons. First, and as mentioned before, one of the in-
clusion criteria in the original study was to have a
FAST score 518, which means that patients were
markedly impaired in their psychosocial functioning
at baseline. In addition, patients had to have a score
of at least 4 points in the cognitive domain of this
scale; this indicated that patients presented neurocog-
nitive complaints detected by the clinician, since this
scale is not self-administered. Clinicians hereby took
into account not only patients’ subjective complaints
but also the information by relatives and clinical
history. Second, patients in the present study were
recruited from different specialized reference centres
in Spain which usually treat difficult-to-treat and se-
vere cases, hence this potential source of bias cannot
be ruled out. Finally, another reason for the discrep-
ancy of our results compared with those of Martino
et al. (2014) may be the different percentage of BD-I
and BD-II patients in each sample. While in the
study of Martino et al. (2014), BD-I and BD-II were
equally distributed (48% BD-I and 52% BD-II), in our
sample, the vast majority of patients were diagnosed
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with BD-I (up to 76%), who usually show more severe
neurocognitive deficits than BD-II patients (Sole et al.
2011). All these differences taken together may help
to explain the discrepancy of impaired patients in
both studies, even following the same method as
described by Martino et al. (2014).
Methodological caveats of our study must be taken
into account when translating results to clinical prac-
tice. First, the 6-month follow-up period is short and
the results cannot be generalizable for long-term out-
come. For the same reason, evident conclusions cannot
be deduced whether the improvement remains stable
or varies over time. Second, as this was an exploratory
subanalysis, we have not conducted any statistic pro-
cedure to control for multiple comparisons when ana-
lysing neurocognition; instead we selected a number of
variables based on previous literature and on neuro-
cognitive domains we work on in the functional re-
mediation programme. Despite all, caution is needed,
since only one out of 11 comparisons (delayed recall)
among the neurocognitive variables was found to be
statistically significant, and a trend was detected for
another variable (verbal learning).
Finally, as stated before, the majority of subjects
included in this trial were chronic patients with mul-
tiple admissions and with marked functional impair-
ment which might interfere with a generalization of
less severe cases with bipolar disorder.
Despite the previous limitations, this study shows
that functional remediation at 6-month follow-up is ef-
fective not only at improving psychosocial functioning,
but also at enhancing delayed free recall in the CVLT in
a sample of patients with neurocognitive impairment.
It supports the notion that neurocognitive enhance-
ment is an active ingredient of functional remediation,
at least in this subsample of patients, and that verbal
memory seems to be more amenable to treatment
than other neurocognitive domains. If the present
results are confirmed by further studies, these findings
may have important consequences in treating chronic
bipolar patients, bringing hope to the subset of patients
with neurocognitive and functional decline, and for
whom there is the utmost unmet need (Reinares et al.
2014).
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